Technical Analysis for GRTS - Gritstone Oncology, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Spinning Top | Other | 5.46% | |
| NR7 | Range Contraction | 5.46% | |
| NR7-2 | Range Contraction | 5.46% | |
| Narrow Range Bar | Range Contraction | 5.46% | |
| Wide Bands | Range Expansion | 5.46% | |
| Down 3 Days in a Row | Weakness | 5.46% | |
| Down 4 Days in a Row | Weakness | 5.46% |
| Alert | Time |
|---|---|
| Up 10% | 1 day ago |
| 60 Minute Opening Range Breakout | 2 days ago |
| Up 5% | 2 days ago |
| Rose Above Previous Day's High | 2 days ago |
| Up 3% | 2 days ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGE™, which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient’s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients’ TSNA to drive the patient’s immune system to attack and destroy tumors.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Immune System Immunotherapy Oncology Tumor Cancer Immunotherapy Machine Learning Virotherapy Immunotherapies Biopsy Tumor Cell
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Immune System Immunotherapy Oncology Tumor Cancer Immunotherapy Machine Learning Virotherapy Immunotherapies Biopsy Tumor Cell
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.33 |
| 52 Week Low | 0.6716 |
| Average Volume | 3,182,529 |
| 200-Day Moving Average | 1.81 |
| 50-Day Moving Average | 1.41 |
| 20-Day Moving Average | 0.84 |
| 10-Day Moving Average | 0.85 |
| Average True Range | 0.11 |
| RSI (14) | 36.71 |
| ADX | 31.69 |
| +DI | 18.25 |
| -DI | 26.83 |
| Chandelier Exit (Long, 3 ATRs) | 0.71 |
| Chandelier Exit (Short, 3 ATRs) | 1.01 |
| Upper Bollinger Bands | 1.02 |
| Lower Bollinger Band | 0.66 |
| Percent B (%b) | 0.37 |
| BandWidth | 43.02 |
| MACD Line | -0.14 |
| MACD Signal Line | -0.16 |
| MACD Histogram | 0.0293 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.91 | ||||
| Resistance 3 (R3) | 0.91 | 0.87 | 0.89 | ||
| Resistance 2 (R2) | 0.87 | 0.83 | 0.87 | 0.88 | |
| Resistance 1 (R1) | 0.83 | 0.82 | 0.85 | 0.83 | 0.87 |
| Pivot Point | 0.79 | 0.79 | 0.79 | 0.79 | 0.79 |
| Support 1 (S1) | 0.75 | 0.75 | 0.77 | 0.75 | 0.70 |
| Support 2 (S2) | 0.70 | 0.74 | 0.71 | 0.69 | |
| Support 3 (S3) | 0.67 | 0.70 | 0.69 | ||
| Support 4 (S4) | 0.67 |
